1. Ferguson J, Sandrock A (2003) Important New Prescribing Information. http://www.fda.gov/medwatch/SAFET Y/2003/avonex_deardoc.pdf (Accessed 16 Dec 2003)
2. Gehshan A, Ruebig A, Salesse M (2003) Important new safety information: Hepatic injury associated with beta-interferon treatment for Multiple Sclerosis http://www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/beta-interferon_hpc_e.pdf (Accessed 16 Dec 2003)
3. CDER-PHRMA-AASLD (2000) Drug-induced hepatotoxicity White Paper Postmarketing Considerations. http:www//fda.gov/cder/livertox/postmarket.pdf (Accessed 28 July 2003)
4. Lewis JA (1981) Post-marketing surveillance?how many patients? Trends Pharmacol Sci 2:93?94
5. Rawlins MD (1988) Spontaneous reporting of adverse drug reactions I: The data. Br J Clin Pharmacol 26:1?5